Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

A Human FcgRIIa (H131 variant)-specific Reporter Assay for Evaluating Antibody Activity in Antibody-dependent Phagocytosis ADCP Pathway Activation

Part # PS225


Teresa Surowy, Rich Moravec, Denise Garvin, Aileen Paguio and Frank Fan
R&D, Promega Corporation, 2800 Woods Hollow Road, Madison, WI 53711, USA

We describe here our development and evaluation of a human FcgRIIa (H131 variant)-specific reporter bioassay for quantifying antibody bioactivity in ADCP pathway activation. The H131 variant is able to bind all human IgG isotypes. The assay uses dual-engineered Jurkat effector cells that express the receptor and mediate FcgRIIa–dependent NFAT activation of reporter luciferase expression only when receptors are bound by target cell-bound antibodies.

Printed in USA 9/2014.